Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Galapagos NV
Merck KGaA
Paradigm Biopharmaceuticals Ltd
Ribomic Inc
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles
GLPG-1972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-6495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADAMTS4 and ADAMTS5 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products
A Disintegrin And Metalloproteise With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteise With Thrombospondin Motifs 11 or Aggrecase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
Jun 11, 2019: Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
Apr 16, 2019: Paradigm’s knee osteoarthritis study meets secondary endpoints
Feb 14, 2019: Paradigm’s orphan phase 2/3 clinical program progresses
Nov 27, 2018: Galapagos receives Fast Track desigtion from FDA for GLPG1972/S201086 in osteoarthritis
Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction
Sep 25, 2018: Galapagos doses first patient in Phase ll trial of GLPG1972/S201086
Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Galapagos NV, H1 2020
Pipeline by Merck KGaA, H1 2020
Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Dormant Projects, H1 2020